Search Within

Center for Hematologic Malignancies

Formats
  1. Journal Article (6195)
  2. Meeting Abstract (6166)
  3. Review (401)
  4. Book Section (216)
  5. Editorial (172)
  6. Research Letter (160)
  7. Guidelines (83)
  8. Conference Paper (70)
  9. Correspondence (61)
  10. Miscellaneous (19)
  11. Book Whole (10)
Groups
  1. Department of Medicine (11094)
  2. Hematologic Malignancies, Division of (10645)
  3. GSK Faculty (5449)
  4. Adult Leukemia (3723)
  5. Sloan Kettering Institute Faculty (3375)
  6. Hematologic Malignancies Research (3005)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (946)
  3. Ross Levine (787)
  4. Andrew Zelenetz (785)
  5. Steven Horwitz (671)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (317)
  2. 2024 (704)
  3. 2023 (877)
  4. 2022 (830)
  5. 2021 (802)
  6. 2020 (874)

More Years

Publications
  1. Blood (3413)
  2. Journal of Clinical Oncology (869)
  3. Biology of Blood and Marrow Transplantation (602)
  4. Clinical Lymphoma, Myeloma and Leukemia (304)
  5. Cancer Research (300)
  6. Haematologica (268)

More Publications

Publishers
  1. American Society of Hematology (3684)
  2. Elsevier Inc. (1669)
  3. Nature Publishing Group (1118)
  4. American Society of Clinical Oncology (918)
  5. American Association for Cancer Research (680)
  6. Wiley Blackwell (437)

More Publishers

Results (13553)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MLL exons 4-8 duplication in a patient with CALR-mutated essential thrombocythemia
    Meeting Abstract

    Mantha, S.; Levine, R. L.; Rampal, R. K.
    Blood (2014)

    Fulltext@MSK | Save
  • Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era
    Meeting Abstract

    Mantha, S.; Goldman, D.; Devlin, S. M.; Lee, J. W.; Zannino, D.; Douer, D.; Iland, H. J.; Litzow, M. R.; Stein, E. M.; Appelbaum, F.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • High dose daunorubicin improves survival in AML up to age 60, across all cytogenetic Risk groups including patients with unfavorable cytogenetic risk, and FLT3-ITD mutant AML: Updated analyses from Eastern Cooperative Oncology trial E1900
    Meeting Abstract

    Luskin, M. R.; Lee, J. W.; Fernandez, H. F.; Lazarus, H. M.; Rowe, J. M.; Tallman, M. S.; Paietta, E. M.; Litzow, M.; Abdel-Wahab, O.; Patel, J. P.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Results of the ECOG E1900 trial in younger adults with AML using an event free survival endpoint are concordant with results based on overall survival: Potential for a surrogate endpoint to facilitate rapid approval of therapies in AML
    Meeting Abstract

    Luskin, M. R.; Lee, J. W.; Fernandez, H. F.; Lazarus, H. M.; Rowe, J. M.; Tallman, M. S.; Paietta, E. M.; Litzow, M.; Abdel-Wahab, O.; Patel, J. P.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Patterns of infectious morbidity in patients with Waldenstrom's macroglobulinaemia/lymphoplasmacytic lymphoma: A population-based study
    Meeting Abstract

    Lund, S. H.; Hultcrantz, M.; Goldin, L.; Landgren, O.; Bjorkholm, M.; Turesson, I.; Kristinsson, S. Y.
    Blood (2014)

    Fulltext@MSK | Save
  • Loss of TET2 function in myelodysplastic syndrome results in intragenic hypermethylation and alterations in mRNA splicing
    Meeting Abstract

    Lord, A. M.; Clement, K.; Schneider, R. K.; Marie, M.; Chen, M. C.; Levine, R. L.; Mullally, A.; Galili, N.; Ali, A. M.; Raza, A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • A randomized phase II trial of three novel regimens for relapsed/refractory acute myeloid leukemia (AML) demonstrates encouraging results with a flavopiridol-based regimen: Results of Eastern Cooperative Oncology Group (ECOG) trial E1906
    Meeting Abstract

    Litzow, M. R.; Wang, X. V.; Carroll, M. P.; Karp, J. E.; Ketterling, R.; Kaufmann, S. H.; Lazarus, H. M.; Luger, S. M.; Paietta, E. M.; Rowe, J. M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • IL-22 is an intestinal stem cell growth factor, and IL-22 administration in vivo reduces morbidity and mortality in murine GvHD
    Meeting Abstract

    Lindemans, C. A.; Mertelsmann, A.; O'Connor, M. H.; Dudakov, J. A.; Jenq, R.; Velardi, E.; Young, L. F.; Smith, O. M.; Lawrence, G.; Luo, N.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies
    Meeting Abstract

    Lesokhin, A. M.; Ansell, S. M.; Armand, P.; Scott, E. C.; Halwani, A.; Gutierrez, M.; Millenson, M. M.; Cohen, A. D.; Schuster, S. J.; Lebovic, D.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Phase 2 study of bendamustine in combination with dexamethasone (Ben/Dex) in patients with previously-treated systemic light chain (AL) amyloidosis
    Meeting Abstract

    Lentzsch, S.; Comenzo, R. L.; Osman, K.; Zikaras, K.; Backenroth, D.; Tsai, W. Y.; Sanchorawala, V.; Landau, H.
    Blood (2014)

    Fulltext@MSK | Save